Novartis AG (NOVN) - Financial and Strategic SWOT Analysis Review

Date: December 20, 2016
Pages: 98
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: N425DFFCE9DEN
Leaflet:

Download PDF Leaflet

Novartis AG (NOVN) - Financial and Strategic SWOT Analysis Review
Novartis AG (NOVN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Novartis AG (Novartis) is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic products for the treatment of diseases and disorders in humans and animals. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic diseases, respiratory diseases, immune disorders and infections, among others. The company offers eye care products through its subsidiary, Alcon; and generics through Sandoz. It also offers vaccines and over-the-counter (OTC) products. Novartis carries out research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company has operations across Asia-Pacific, North America, Europe, Africa, and Latin America. Novartis is headquartered in Basel, Switzerland.

Novartis AG Key Recent Developments

Dec 12, 2016: Novartis launches SMS for Life 2.0 in Nigeria to help improve access to essential medicines
Nov 29, 2016: Novartis Access shares one-year learnings and announces memorandum of understanding with Rwanda
Nov 16, 2016: Novartis data at ASH and SABCS showcase latest innovations in development for patients with blood disorders and breast cancer
Nov 14, 2016: Novartis improves ranking in 2016 Access to Medicine Index
Oct 25, 2016: Novartis delivered solid third quarter with Growth Products offsetting Gleevec patent expiration; several positive readouts for potential blockbusters

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

    Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

    Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

    Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

    Note: Some sections may be missing if data is unavailable for the company
  • SECTION 1 - ABOUT THE COMPANY

    Novartis AG - Key Facts
    Novartis AG - Key Employees
    Novartis AG - Key Employee Biographies
    Novartis AG - Major Products and Services
    Novartis AG - Pharmaceutical Pipeline Products Data
    Novartis AG, Pipeline Products by Therapy Area
    Novartis AG, Pipeline Products by Development Phase
    Novartis AG - History
    Novartis AG - Company Statement
    Novartis AG - Locations And Subsidiaries
    Head Office
    Other Locations & Subsidiaries

    SECTION 2 – COMPANY ANALYSIS

    Novartis AG - Business Description
    Novartis AG - Corporate Strategy
    Novartis AG - SWOT Analysis
    SWOT Analysis - Overview
    Novartis AG - Strengths
    Novartis AG - Weaknesses
    Novartis AG - Opportunities
    Novartis AG - Threats
    Novartis AG - Key Competitors

    SECTION 3 – COMPANY FINANCIAL RATIOS

    Financial Ratios - Capital Market Ratios
    Financial Ratios - Annual Ratios
    Performance Chart
    Financial Performance
    Financial Ratios - Interim Ratios
    Financial Ratios - Ratio Charts

    SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

    Novartis AG, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
    Novartis AG, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
    Novartis AG, Recent Deals Summary

    SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

    Dec 12, 2016: Novartis launches SMS for Life 2.0 in Nigeria to help improve access to essential medicines
    Nov 29, 2016: Novartis Access shares one-year learnings and announces memorandum of understanding with Rwanda
    Nov 16, 2016: Novartis data at ASH and SABCS showcase latest innovations in development for patients with blood disorders and breast cancer
    Oct 25, 2016: Novartis delivered solid third quarter with Growth Products offsetting Gleevec patent expiration; several positive readouts for potential blockbusters
    Sep 15, 2016: Novartis Foundation showcases progress in leprosy elimination programs at 19th International Leprosy Congress
    Aug 12, 2016: 6 Novartis Korean executives indicted for bribing doctors
    Jul 19, 2016: Novartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospects
    May 25, 2016: Novartis highlights its strong foundation for long-term, sustainable growth at the third Meet Novartis Management event
    May 24, 2016: COTA Increases Cross-Industry Support With the Addition of Celgene, Foundation Medicine HealthScape Advisors and Novartis as Strategic Investors
    May 18, 2016: Novartis to present pivotal data in hematologic and solid tumor cancers at 2016 ASCO Annual Meeting

    SECTION 6 – APPENDIX

    Methodology
    Ratio Definitions
    About GlobalData
    Contact Us
    Disclaimer

    LIST OF TABLES

    Novartis AG, Key Facts
    Novartis AG, Key Employees
    Novartis AG, Key Employee Biographies
    Novartis AG, Major Products and Services
    Novartis AG, Number of Pipeline Products by Therapy Area
    Novartis AG, Number of Pipeline Products by Development Stage
    Novartis AG, History
    Novartis AG, Subsidiaries
    Novartis AG, Key Competitors
    Novartis AG, Ratios based on current share price
    Novartis AG, Annual Ratios
    Novartis AG (Cont...1), Annual Ratios
    Novartis AG, Interim Ratios
    Novartis AG, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
    Novartis AG, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
    Novartis AG, Recent Deals Summary
    Currency Codes
    Capital Market Ratios
    Equity Ratios
    Profitability Ratios
    Cost Ratios
    Liquidity Ratios
    Leverage Ratios
    Efficiency Ratios

    LIST OF FIGURES

    Novartis AG, Pipeline Products by Therapy Area
    Novartis AG, Pipeline Products by Development Phase
    Novartis AG, Performance Chart (2011 - 2015)
    Novartis AG, Ratio Charts
    Novartis AG, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
    Novartis AG, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016
    Skip to top


    Ask Your Question

    Novartis AG (NOVN) - Financial and Strategic SWOT Analysis Review
    Company name*:
    Contact person*:
    Phone/fax*:
    Email*:
    Request invoice
    Your enquiry:
    Please click on a Check Box below to confirm you are not a robot: